Clinical trials: Urinary Symptoms
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Urinary Incontinence, Overactive Bladder
Tactile Imaging and Electromyography
Urinary incontinence (UI) and overactive bladder (OAB) in women has high prevalence which is increasing with the age. In adults aged 40 and older in the US demonstrated prevalence rate of 27.2% among man and 43.1% among women…
- Trial name
- NCT03477214
- Testing
- Biomechanical and electromyography mapping
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Advanced Tactile Imaging, Inc.
Urinary Stress Incontinence
Efficacy and Safety of Duloxetine
The purpose of this study is to monitor the long term safety and efficacy of duloxetine in the treatment of severe pure genuine stress incontinence.
- Trial name
- NCT00190619
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder, Neurogenic
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old.
- Trial name
- NCT01557244
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin
- Where
- 84 sites in United States, Belgium and 23 more
- Volunteers
- 181 people
- Sponsor
- Pfizer
Bladder Cancers
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)
The purpose of the study is the identification of chromosomal aberrations in urine samples. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of UroVysion…
- Trial name
- NCT01264744
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- Applied Spectral Imaging Ltd.
Prostatic Hyperplasia
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
The primary objective of the study is to demonstrate the superiority of SL77.0499-10 10mg once daily over placebo and the non-inferiority versus tamsulosin hydrochloride after 12 weeks treatment in terms of the efficacy in…
- Trial name
- NCT00399464
- Testing
- alfuzosin
- Where
- Japan
- Volunteers
- 1,177 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia (BPH)
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation.
- Trial name
- PERMIN (NCT01604811)
- Testing
- Permixon® 160 mg, Tamsulosine Arrow LP
- Where
- 32 sites in France, Italy and 2 more
- Volunteers
- 206 people
- Sponsor
- Pierre Fabre Medicament
Urinary Incontinence, Urinary Obstruction
NXT Post-Market Clinical Follow-up
NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
- Conditions
- Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
- Trial name
- NCT06336304
- Testing
- Urodynamic procedure
- Where
- 5 sites in United States
- Volunteers
- 163 people
- Sponsor
- Laborie Medical Technologies Inc.
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Overactive Bladder
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance…
- Trial name
- POTTOR (NCT01488578)
- Testing
- Tolterodine tartrate
- Volunteers
- 11,157 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Urinary Stress Incontinence
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
- Trial name
- NCT00190606
- Testing
- Duloxetine, Pelvic Floor Muscle Training (PFMT), Imitation PFMT
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Respiratory Tract Infections, Urinary Tract Infections
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections.
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Intraabdominal Infections
- Trial name
- NCT03744741
- Testing
- HostDx Sepsis
- Where
- 7 sites in United States, Greece
- Volunteers
- 585 people
- Sponsor
- Inflammatix
Prostatic Hyperplasia
ALF-ONE : ALFuzosin ONcE Daily
The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms…
- Trial name
- NCT00280605
- Testing
- Alfuzosin
- Volunteers
- 200 people
- Sponsor
- Sanofi
Urinary Bladder, Overactive
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB).
- Trial name
- NCT01314872
- Testing
- Vibegron, Tolterodine ER
- Volunteers
- 1,395 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Transitional Cell, Bladder Cancer
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer.
- Conditions
- Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
- Trial name
- NCT00722553
- Testing
- Pralatrexate Injection, Vitamin B12, Folic Acid
- Where
- 19 sites in United States, Argentina and 4 more
- Volunteers
- 30 people
- Sponsor
- Acrotech Biopharma Inc.
Urinary Bladder Overactive, Overactive Bladder
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
- Trial name
- PERSPECTIVE (NCT02386072)
- Testing
- mirabegron, antimuscarinic medication
- Where
- 92 sites in United States, Canada
- Volunteers
- 1,524 people
- Sponsor
- Astellas Scientific & Medical Affairs, Inc.
Calculi, Renal, Calculi, Urinary
Modified SOLTIVE Study
This is a study to collect procedural data during the use of the SOLTIVE™ Premium SuperPulsed Laser System in the treatment of bladder, ureteral, and kidney stones and BPH to inform the development of software algorithms.
- Conditions
- Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
- Trial name
- NCT07838077
- Testing
- SOLTIVE Premium SuperPulsed Laser System
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Olympus Corporation of the Americas
Urethral Stricture
ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
ROBUST III is a prospective, multi-center, randomized controlled adaptive sample size clinical trial to establish the safety and effectiveness for the Optilume Stricture Drug Coated Balloon (DCB).
- Trial name
- ROBUST-III (NCT03499964)
- Testing
- Optilume Drug Coated Balloon (DCB), Control Treatment
- Where
- 22 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- Urotronic Inc.
Overactive Bladder
Toviaz Post Marketing Surveillance Study
The objective of this study is to determine the problems and questions of safety and efficacy of Toviaz® under the standard conditions of usage.
- Trial name
- NCT00879398
- Testing
- Toviaz treatment
- Where
- 82 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics